Jordana Joy

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser.

The trial aims to evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment (AZR-MD-001) 0.5% compared to vehicle in patients with abnormal meibomian gland function (MGD) and associated symptoms of dry eye disease (DED)

The gel is a cross-linked hyaluronic acid derivative and has been cleared by the FDA to temporarily block tear drainage by the occlusion of the canalicular system.

Data from the trial found that MyopiaX proved clinically safe and tolerable, in addition to showing clinical effect on the rate of myopia progression.

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.

Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium.

Shelley Cutler, OD, FAAO, gives an overview of how keratoconus diagnosis and treatment over the past 40 years has changed and evolved as well as some key insights from the IKA 2024 Symposium.

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

William Trattler, MD, talked about his session at the IKA 2024 Symposium that discussed the progression of keratoconus in patients and just how likely it is for them to progress and the importance of following up with these patients.

Kourtney Houser, MD, and Kendall Donaldson, MD, MS, had a session where they talked about the early diagnosis of keratoconus and key indicators in tomography that might help diagnose keratoconus before vision loss.

While it fell short of the primary endpoint of improvement of non-proliferative diabetic retinopathy (NPDR) of at least 2 Diabetic Retinopathy Severity Scale (DRSS) levels as of week 36, DURAVYU did demonstrate stable or improved disease severity with reduced rates of NPDR in 9 months.

Anthony Wallace, US Surgical vice president and general manager for Bausch + Lomb, reviews the latest advancements and updates in an interview with Ophthalmology Times.

The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Multiple symptomatic improvements, as well as tear film break-up time improvements and a reduction in ocular pain, were noted.

Several eye care products sold at Walmart and CVS locations have been recalled due to FDA findings during a facility inspection conducted earlier this month.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.